Huang Xiufeng, Li Hongxing, Liu Lu, Zhang Yu
Department of Respiratory and Critical Care Medicine, Wuxi Ninth People's Hospital Affiliated to Soochow University, No.999 Liangxi Road, Binhu District, Wuxi, Jiangsu, 214000, China.
Department of Respiratory and Critical Care Medicine, Taicang First People's Hospital, Suzhou, Jiangsu, 215400, China.
J Cardiothorac Surg. 2025 Jul 19;20(1):308. doi: 10.1186/s13019-025-03544-1.
This study aimed to assess the auxiliary diagnostic efficacy of Pentraxin 3 (PTX3) as a biomarker for pulmonary tuberculosis (TB) by analyzing its levels in plasma and bronchoalveolar lavage fluid (BALF) in TB patients. Given the limitations of current TB diagnostic methods, the investigation also sought to evaluate the possible auxiliary help of PTX3 in distinguishing TB from other pulmonary conditions.
The bioinformatic analysis utilized the Gene Expression Omnibus (GEO) dataset (GSE34608), including peripheral blood samples from individuals with TB, sarcoidosis, and healthy controls. Clinical specimens were obtained from hospitalized patients between January 2020 and March 2022, comprising 126 peripheral blood samples and 68 BALF samples. PTX3 levels were measured via enzyme-linked immunosorbent assays (ELISA), with subsequent statistical analyses conducted to assess the auxiliary diagnostic efficacy of PTX3 through ROC curve analysis.
The analysis of the GEO dataset revealed a notable increase in PTX3 levels in the peripheral blood of TB patients compared to controls, with an area under the curve (AUC) of 0.889. However, no significant differences in plasma PTX3 levels were observed among TB, community-acquired pneumonia (CAP), and lung cancer patients in clinical samples (AUC: 0.472). Conversely, PTX3 levels in BALF were significantly elevated in TB patients compared to individuals with CAP and lung cancer (P < 0.001), with an AUC of 0.806, along with a sensitivity of 0.800 and specificity of 0.810, suggesting its potential auxiliary diagnostic utility.
Plasma PTX3 levels have limited diagnostic utility in distinguishing tuberculosis from other pulmonary conditions, whereas BALF PTX3 levels exhibit more possible auxiliary diagnosis ability as an auxiliary diagnostic indicator, offering a localized assessment of lung inflammation. BALF PTX3 could be a helpful adjunct in diagnosing TB, particularly in cases where conventional sputum-based tests are inconclusive. Further research is needed to validate these findings.
本研究旨在通过分析肺结核(TB)患者血浆和支气管肺泡灌洗液(BALF)中 Pentraxin 3(PTX3)的水平,评估其作为肺结核生物标志物的辅助诊断效能。鉴于当前结核病诊断方法的局限性,该研究还试图评估 PTX3 在区分结核病与其他肺部疾病方面可能提供的辅助作用。
生物信息学分析利用了基因表达综合数据库(GEO)数据集(GSE34608),包括结核病患者、结节病患者和健康对照者的外周血样本。临床标本取自 2020 年 1 月至 2022 年 3 月期间住院患者,包括 126 份外周血样本和 68 份 BALF 样本。通过酶联免疫吸附测定(ELISA)测量 PTX3 水平,随后进行统计分析,通过 ROC 曲线分析评估 PTX3 的辅助诊断效能。
对 GEO 数据集的分析显示,与对照组相比,结核病患者外周血中 PTX3 水平显著升高,曲线下面积(AUC)为 0.889。然而,在临床样本中,结核病、社区获得性肺炎(CAP)和肺癌患者的血浆 PTX3 水平未观察到显著差异(AUC:0.472)。相反,与 CAP 和肺癌患者相比,结核病患者 BALF 中的 PTX3 水平显著升高(P < 0.001),AUC 为 0.806,敏感性为 0.800,特异性为 0.810,表明其具有潜在的辅助诊断效用。
血浆 PTX3 水平在区分结核病与其他肺部疾病方面的诊断效用有限,而 BALF PTX3 水平作为辅助诊断指标表现出更强的辅助诊断能力,可对肺部炎症进行局部评估。BALF PTX3 在结核病诊断中可能是一种有用的辅助手段,特别是在传统痰检结果不明确的情况下。需要进一步研究来验证这些发现。